CINDY DEREQUITO: Open Payments
NPI 1134745185 · HOLLYWOOD, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,819 in 231 payments from 21 companies in 2025. Trend: 2023 $3,802 · 2024 $4,054 · 2025 $4,819
Food & beverage: $4,819
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 22 | $614 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $483 |
| Janssen Pharmaceuticals, Inc | 18 | $406 |
| Otsuka America Pharmaceutical, Inc. | 16 | $391 |
| ABBVIE INC. | 21 | $386 |
| Vanda Pharmaceuticals Inc. | 11 | $317 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $315 |
| Teva Pharmaceuticals USA, Inc. | 27 | $312 |
| Bausch Health US, LLC | 13 | $292 |
| Alkermes, Inc. | 14 | $280 |
Products named: INGREZZA, CAPLYTA, REXULTI, VRAYLAR, TRINTELLIX, HETLIOZ, APLENZIN, ARISTADA.
Industry payments across FL — which companies pay providers there.
